Ready to introduce the medical use of Cannabis in Italy
CBD is the medical abbreviation for cannabidiol, metabolite of the more famous Cannabis, within which it is the substance present in the greatest proportion, after THC. Unlike the latter, however, CBD is not psychoactive, does not create addiction and has significant relaxing, anti-inflammatory and pain-relieving properties. It is a compound with great pharmacological potential, but still little studied; an ancient remedy that we are rediscovering, but that, to date, is only available in an amateur and non-professional market.
Materia Medica Processing was born from a multidisciplinary team, with the aim of introducing into the Italian market a phytocomplex – that is, an integral extract of the hemp plant, devoid of any psychotropic action. A product that works both by alleviating the symptoms of anxiety and stress and improving the mood and reducing any chronic and generalized inflammation; it is no coincidence that one of the most interesting areas of application is sports, since it is not considered a doping substance.
As Giovanni Isoldi explains in his interview, there is a large market, that in Italy arises from a regulatory gap, an emerging market that abroad is not overlooked, like in Canada, Israel and the United States. And it is precisely in this context that Materia Medica Processing introduces its value proposition: a controlled product, highly traceable and of high quality standards, thanks to the most advanced technologies and a specific know-how on the cannabinoid chemistry.
By joining TLS, Materia Medica Processing has been able to rely on a provider of infrastructures and services (a critical supporting figure for a startup); today, however, the Foundation is in all respects a trusted partner, with whom to share choices, strategies and a vision of the future.
Materia Medica Processing has been incubated in TLS since 2018.